Target: ₹6,230CMP: ₹5,497.80Alkem Laboratories’ EBITDA grew 32 per cent year on year, led by 15 per cent sales growth, higher gross margin (65.9 per cent), offset by higher costs (staff/R&D/SG&A +16 per cent/45 per cent/28 per cent).The company expects:
India business to beat IPM growth by 100-150 bps in FY27, led by increasing share from chronic share
scale-up in GLP-1 franchisee, traction from key therapies and new launches
its MR addition will remain strategic with focus on chronic business
to remain cautious on near-term gross and EBITDA margin due to cost escalations ed by geopolitical issue, its targets to improve EBITDA margin by 100 bps per annum for the next few years
